Knight Capital Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Knight Capital Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$1.66M	Buy	+17,989	New	+$1.73M	0.03%	647

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Knight Capital Group's ALXN Position: Q2 2013 in Review

Knight Capital Group opened a new position in Alexion Pharmaceuticals (ALXN) in Q2 2013: 17,989 shares worth $1.66M. The stake represents 0.03% of the portfolio and ranks #647 among its holdings.

406 funds tracked by Wall St. Rank hold ALXN as of Q2 2013.

Knight Capital Group held 17,989 shares of Alexion Pharmaceuticals worth $1.66M as of Q2 2013.
Alexion Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
Alexion Pharmaceuticals made up 0.03% of Knight Capital Group's portfolio in Q2 2013, its #647 holding.
406 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.